CriticalAntiretroviral, non-nucleoside reverse transcriptase inhibitor (NNRTI)×Second-generation systemic triazole antifungal
Updated · Methodology
Mechanism
Efavirenz induces the enzymes CYP3A4, CYP2B6 and UGT1A1, so levels of drugs metabolised by them may fall (efavirenz summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and efavirenz label, US Food and Drug Administration, FDA). CYP3A4 and CYP3A5 metabolise isavuconazole. The European isavuconazole SmPC lists efavirenz among moderate CYP3A4/5 inducers that may markedly lower isavuconazole levels (isavuconazole SmPC, European Medicines Agency, EMA). In the other direction, isavuconazole mildly induces CYP2B6, which metabolises efavirenz, so efavirenz levels may also fall (EMA). The two drugs have not been studied together, and the documents give no figures for this pair (EMA).
Symptoms
Efavirenz may markedly lower isavuconazole levels, and isavuconazole may lower efavirenz levels (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). The size of these effects has not been measured. Both drugs can damage the liver. Hepatitis, including fulminant hepatitis with liver failure, liver transplantation or death, has been reported with efavirenz (efavirenz label, US Food and Drug Administration, FDA). Hepatitis, cholestasis and liver failure, including fatal cases, have been reported in seriously ill patients treated with azole antifungals, isavuconazole among them (isavuconazole label, FDA). QTc prolongation has been observed with efavirenz (efavirenz SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), while isavuconazole shortens the QTc interval, more so at higher concentrations (EMA). The documents do not say how these effects combine.
Management
The combination is contraindicated: the European isavuconazole SmPC names efavirenz explicitly among moderate CYP3A4/5 inducers that must not be given with isavuconazole (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). The US isavuconazole label contraindicates only strong CYP3A4 inducers and does not name efavirenz (isavuconazole label, US Food and Drug Administration, FDA). The efavirenz documents do not name isavuconazole (efavirenz SmPC and label, Spanish Agency of Medicines and Medical Devices, AEMPS, and FDA). No document gives a waiting time between stopping efavirenz and starting isavuconazole. The half-life of efavirenz after multiple doses is 40–55 hours (AEMPS), and the mean half-life of isavuconazole is 130 hours (FDA). The Spanish efavirenz SmPC recommends monitoring liver enzymes in patients who also take other drugs that can damage the liver (AEMPS). The US label recommends monitoring them before and during treatment in all patients (FDA). With isavuconazole, evaluate liver tests at the start and during treatment (FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.5 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4, 4.5, 4.9 y 5.2
- FDA: CRESEMBA (isavuconazonium sulfate) prescribing information (2025)– FDA, DailyMed setid 8f7f73b8-586a-4df0-935f-fecd4696c16c (Astellas Pharma US), revisión 04/2025 (versión 21), secciones 4, 5.1, 5.5, 7, 10 y 12.3
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.3 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Efavirenz (nº registro 79191), sección 4.5 (2025)– AEMPS, CIMA, nº registro 79191 (Efavirenz Aurovitas 600 mg comprimidos recubiertos con película EFG), revisión 04/2025, secciones 4.3, 4.4, 4.5 y 5.2; la autorización del original Sustiva (EU/1/99/110) está revocada
- FDA: Efavirenz tablets (Cipla USA) prescribing information (2024)– FDA, DailyMed setid 92603fa5-7a2c-4bfb-9a70-aadb4fba952c (Cipla USA), versión 7 (effective 31.03.2024, publicada 10.09.2024), secciones 5.1, 5.2, 5.9, 7.1 y 7.2; SUSTIVA en DailyMed solo figura con etiqueta de reenvasador de 2013